Gonococcal vaccines: Public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019
2020/04/28 by Sami L. Gottlieb, Francis Ndowa, Edward W. Hook +19 · 25 citations
Immunology and Microbiology · Social Sciences · #Reproductive tract infections research #Bacterial Infections and Vaccines #Vaccine Coverage and Hesitancy
paper · doi:10.1016/j.vaccine.2020.02.073
Abstract
Renewed interest in developing vaccines against Neisseria gonorrhoeae has been sparked by the increasing threat of gonococcal antimicrobial resistance (AMR) and growing optimism that gonococcal vaccines are biologically feasible. Evidence suggests serogroup B Neisseria meningitidis vaccines might provide some cross-protection against N. gonorrhoeae, and new gonococcal vaccine candidates based on several approaches are currently in preclinical development. To further stimulate investment and accelerate development of gonococcal vaccines, greater understanding is needed regarding the overall value that gonococcal vaccines might have in addressing public health and societal goals in low-, middle-, and high-income country contexts and how future gonococcal vaccines might be accepted and used, if available. In January 2019, the World Health Organization (WHO) convened a multidisciplinary international group of experts to lay the groundwork for understanding the potential health, economic, and societal value of gonococcal vaccines and their likely acceptance and use, and for developing gonococcal vaccine preferred product characteristics (PPCs). WHO PPCs describe preferences for vaccine attributes that would help optimize vaccine value and use in meeting the global public health need. This paper describes the main discussion points and conclusions from the January 2019 meeting of experts. Participants emphasized the need for vaccines to control N. gonorrhoeae infections with the ultimate goals of preventing adverse sexual and reproductive health outcomes (e.g., infertility) and reducing the impact of gonococcal AMR. Meeting participants also discussed important PPC considerations (e.g., vaccine indications, target populations, and potential immunization strategies) and highlighted crucial research and data needs for guiding the value assessment and PPCs for gonococcal vaccines and advancing gonococcal vaccine development.
Citations
Cited by
- Global epidemiology of Neisseria gonorrhoeae in infertile populations: systematic review, meta-analysis and metaregression. [europepmc]
- Comprehensive Bioinformatic Assessments of the Variability of Neisseria gonorrhoeae Vaccine Candidates. [europepmc]
- Antimicrobial Resistance Mechanisms, Multilocus Sequence Typing, and NG-STAR Sequence Types of Diverse Neisseria gonorrhoeae Isolates in KwaZulu-Natal, South Africa. [europepmc]
- Vaccine Candidates for the Control and Prevention of the Sexually Transmitted Disease Gonorrhea. [europepmc]
- HIV pre-exposure prophylaxis and sexually transmitted infections: intersection and opportunity. [europepmc]
- Outer membrane vesicle vaccines for Neisseria gonorrhoeae. [europepmc]
- Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis. [europepmc]
- Bacteria-Mediated Oncogenesis and the Underlying Molecular Intricacies: What We Know So Far. [europepmc]
- Recent Progress Towards a Gonococcal Vaccine. [europepmc]
- Assessment of In Vitro Immunostimulatory Activity of an Adjuvanted Whole-Cell Inactivated Neisseria gonorrhoeae Microparticle Vaccine Formulation. [europepmc]
- Microencapsulated IL-12 Drives Genital Tract Immune Responses to Intranasal Gonococcal Outer Membrane Vesicle Vaccine and Induces Resistance to Vaginal Infection with Diverse Strains of Neisseria gonorrhoeae. [europepmc]
- Projecting the development of antimicrobial resistance in Neisseria gonorrhoeae from antimicrobial surveillance data: a mathematical modelling study. [europepmc]
- The potential impact of a vaccine on Neisseria gonorrhoeae prevalence among heterosexuals living in a high prevalence setting. [europepmc]
- Development of a Tag/Catcher-mediated capsid virus-like particle vaccine presenting the conserved Neisseria gonorrhoeae SliC antigen that blocks human lysozyme. [europepmc]
- Public willingness to receive chlamydia, gonorrhea, syphilis, and trichomoniasis vaccines: a scoping review. [europepmc]
- Promising developments in gonococcal vaccines. [europepmc]
- Vaccine value profile for Neisseria gonorrhoeae. [europepmc]
- Neisseria gonorrhoeae vaccines: a contemporary overview. [europepmc]
- Review of mathematical models of Neisseria gonorrhoeae vaccine impact: Implications for vaccine development. [europepmc]
- Multicentre double-blind randomised placebo-controlled trial evaluating the efficacy of the meningococcal B vaccine, 4CMenB (Bexsero), against Neisseria gonorrhoeae infection in men who have sex with men: the GoGoVax study protocol. [europepmc]
- Cost-effectiveness of 4CMenB Vaccination Against Gonorrhea: Importance of Dosing Schedule, Vaccine Sentiment, Targeting Strategy, and Duration of Protection. [europepmc]
- Investigation into the Interaction between Penicillin-Resistant and Penicillin-Susceptible Gonococcal Penicillin-Binding Protein 2 and Target Phenolic Ligands through Molecular Docking Studies and Structure-Activity Relationship Analysis. [europepmc]
- Modeling gonorrhea vaccination to find optimal targeting strategies that balance impact with cost-effectiveness. [europepmc]
- Beyond behavioural change: prioritising structural solutions to control bacterial sexually transmitted infections. [europepmc]
- Human monoclonal antibodies reveal subdominant gonococcal and meningococcal cross-protective antigens [europepmc]
Related